Posted by Michael Wonder on 02 Aug 2023
PYC Therapeutics gets fast track status from FDA for retinitis pigmentosa treatment
1 August 2023 - PYC Therapeutics has received fast track designation from the US FDA for a new drug aimed at treating degenerative eye disease.
The company announced on Wednesday it would use the designation, which often leads to earlier than anticipated approval in the US, to work with the FDA to advance its VP-001 drug.
